Lisata Therapeutics Inc (LSTA)

[akasidney86]

Others here are undoubtedly better than I at assembling future potential earnings for new drugs, but here's some data: there are about 17.5 million people with T1D and T2D in the States, and the medical bills to treat their disease run an average of $7,900 additional to normal non-diabetic medical bills. (http://care.diabetesjournals.org/content/36/4/1033.full). Obviously, even a small fraction of those numbers mean that CLBS03 would be a blockbuster drug if successful.

If the Sanford Project trial shows promise in lowering C-peptide and endogenous insulin secretion by preserving beta-cell function (this is what CLBS03 is trying to do), and that we will know soon for the group of 18, look out. Good news also; the test being done on the 18 to generate the data is the MMTT test which is considered the gold standard for this question, so there will be no arguments when the data comes in other than over the sample size (super small)... and that will happen regardless of the outcome. If bad data, the company will most likely argue that it's a tiny group. If good, the bears will argue the opposite... it proves nothing.